20 May 2013
Keywords: BioTime, Glycosan, Cell Targetting, Stem cells, Regenerative medicine
Article | 15 February 2011
US biotech BioTime (NYSE Amex: BTX), a company that develops and markets products in the field of stem cells and ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
15 February 2011
16 February 2011
17 May 2013
© 2013 thepharmaletter.com